







































Emmanuel Ifeanyi Obeagu                                                                                                        Asian Journal of Dental and Health Sciences. 2025; 5(3):6-12 

[6]                                                                                                                                                                                                                                              AJDHS.COM 

 

 

Available online at ajdhs.com 

Asian Journal of Dental and Health Sciences 
Open Access to Dental and Medical Research 

Copyright  © 2025 The  Author(s): This is an open-access article distributed under the terms of the CC BY-NC 4.0 
which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the 

original author and source are credited  

 

 

Nitric Oxide Bioavailability and Vascular Dysfunction in Sickle Cell Patients: A 
Pathophysiological Nexus 

* Emmanuel Ifeanyi Obeagu  

Department of Biomedical and Laboratory Science, Africa University, Zimbabwe. 

Article Info: 
_____________________________________________ 
Article History: 

Received   09 May 2025     
Reviewed  29 May 2025 
Accepted   18 June 2025 
Published 15 Sep 2025 

_____________________________________________ 
Cite this article as:  

Obeagu EI, Nitric Oxide Bioavailability and 
Vascular Dysfunction in Sickle Cell Patients: 
A Pathophysiological Nexus, Asian Journal of 
Dental and Health Sciences. 2025; 5(3):6-12                                                                     

DOI: http://dx.doi.org/10.22270/ajdhs.v5i3.134             

Abstract 
_________________________________________________________________________________________________________________ 

Sickle cell disease (SCD) is a genetic disorder characterized by chronic hemolytic anemia, recurrent 
vaso-occlusive crises, and progressive organ damage. One of the central mechanisms driving 
vascular complications in SCD is the impaired bioavailability of nitric oxide (NO), a key molecule 
responsible for regulating vascular tone, inhibiting platelet aggregation, and maintaining endothelial 
integrity. The persistent intravascular hemolysis that occurs in SCD releases free hemoglobin and 
arginase into the circulation, which significantly reduces NO levels and limits its physiological 
effects. Reduced NO availability leads to endothelial dysfunction, characterized by vasoconstriction, 
increased leukocyte adhesion, and a pro-thrombotic state. These vascular changes not only 
contribute to acute events such as pain crises and acute chest syndrome but also underlie long-term 
complications including pulmonary hypertension, stroke, and chronic organ damage. Oxidative 
stress and inflammation further disrupt NO synthesis by impairing endothelial nitric oxide synthase 
(eNOS) activity and uncoupling its function, creating a vicious cycle of vascular injury. 

Keywords: Nitric oxide, sickle cell disease, vascular dysfunction, hemolysis, endothelial health 

*Address for Correspondence:   

Emmanuel Ifeanyi Obeagu, Department of Biomedical and Laboratory Science, Africa University, Zimbabwe 

 

Introduction 

Sickle cell disease (SCD) is a hereditary blood disorder 
characterized by the production of abnormal 
hemoglobin, known as hemoglobin S (HbS). Under low 
oxygen conditions, HbS polymerizes, causing red blood 
cells (RBCs) to adopt a sickled shape, which results in 
vascular occlusion and hemolysis. These sickled cells 
contribute to chronic hemolytic anemia, recurrent vaso-
occlusive episodes, and progressive organ damage. 
Vascular dysfunction is a hallmark feature of SCD, 
playing a central role in the development of both acute 
and chronic complications. Among the key molecular 
players in vascular homeostasis is nitric oxide (NO), a 
potent vasodilator and anti-inflammatory agent 
produced by endothelial cells. However, in SCD, the 
bioavailability of NO is significantly reduced, 
contributing to the pathogenesis of vascular 
complications and poor clinical outcomes 1-2. NO is 
synthesized in endothelial cells by endothelial nitric 
oxide synthase (eNOS) using L-arginine as a substrate. 
Once produced, NO diffuses into smooth muscle cells, 
where it activates soluble guanylate cyclase (sGC), 
leading to the production of cyclic guanosine 
monophosphate (cGMP). This process induces 
vasodilation and maintains vascular tone. Furthermore, 
NO has anti-thrombotic and anti-inflammatory 
properties, preventing the adhesion of platelets and 
leukocytes to the endothelium. In healthy individuals, 

NO maintains vascular homeostasis by regulating blood 
flow, reducing blood clotting, and preventing 
endothelial dysfunction. However, in SCD, NO’s crucial 
role is impaired by multiple pathophysiological factors, 
leading to significant consequences for vascular health 3-

4. 

One of the primary contributors to NO depletion in SCD 
is the chronic hemolysis of sickled red blood cells. The 
release of free hemoglobin from lysed RBCs into the 
bloodstream leads to an increase in cell-free 
hemoglobin levels, which can bind to and scavenge NO. 
This results in the rapid inactivation of NO, thereby 
reducing its bioavailability and function. Furthermore, 
the presence of free hemoglobin promotes oxidative 
stress, which further damages the endothelium and 
reduces the activity of eNOS, the enzyme responsible for 
NO production. As a result, the normal vasodilatory 
effect of NO is diminished, contributing to a state of 
endothelial dysfunction that predisposes individuals 
with SCD to vaso-occlusive crises and other 
cardiovascular complications 5. In addition to the 
scavenging effects of free hemoglobin, the activity of the 
enzyme arginase is significantly elevated in SCD. 
Arginase competes with endothelial nitric oxide 
synthase (eNOS) for the substrate L-arginine, a key 
precursor in the production of NO. Increased arginase 
activity reduces the availability of L-arginine for NO 
synthesis, further exacerbating the deficit of NO in the 

                     Open Access                                                                                                                                                                                                                Review Article                                                                           

http://jddtonline.info/
http://dx.doi.org/10.22270/ajdhs.v5i3.134
https://crossmark.crossref.org/dialog/?doi=10.22270/ajdhs.v5i3.134&amp;domain=pdf
https://orcid.org/0000-0002-4538-0161


Emmanuel Ifeanyi Obeagu                                                                                                        Asian Journal of Dental and Health Sciences. 2025; 5(3):6-12 

[7]                                                                                                                                                                                                                                              AJDHS.COM 

vascular system. This competition between arginase and 
eNOS for L-arginine is a critical factor in the 
pathophysiology of vascular dysfunction in SCD, 
highlighting the importance of understanding how this 
enzyme dysregulation contributes to the disease 
process 6-7. The consequences of reduced NO 
bioavailability in SCD are far-reaching, extending 
beyond the immediate effects of vasoconstriction and 
platelet aggregation. Chronic NO depletion in SCD 
promotes endothelial activation, characterized by the 
upregulation of adhesion molecules such as VCAM-1 and 
ICAM-1. These molecules facilitate the adhesion of 
sickled erythrocytes and leukocytes to the vascular 
endothelium, leading to further obstruction of blood 
flow and exacerbating the process of vaso-occlusion. 
Moreover, the reduced anti-thrombotic effect of NO 
increases the risk of thrombus formation and deep vein 
thrombosis. Over time, these processes contribute to the 
development of long-term vascular complications, such 
as pulmonary hypertension, stroke, and organ damage, 
particularly in the lungs, kidneys, and brain 8-9. 

Nitric Oxide and Endothelial Homeostasis 

Nitric oxide (NO) is a pivotal signaling molecule that 
plays a critical role in maintaining endothelial 
homeostasis, which is essential for vascular health. The 
endothelial cells lining the blood vessels are responsible 
for regulating vascular tone, blood flow, and immune 
cell trafficking. These cells continuously interact with 
circulating blood components, and NO are central to 
these interactions, ensuring that the blood vessels 
function properly and that the delicate balance between 
vasodilation and vasoconstriction is maintained 10. 
Endothelial cells synthesize NO through the action of 
endothelial nitric oxide synthase (eNOS), which 
converts L-arginine into NO in the presence of oxygen. 
NO diffuses from the endothelium into the smooth 
muscle cells of the blood vessel walls, where it activates 
soluble guanylate cyclase (sGC). This leads to the 
generation of cyclic guanosine monophosphate (cGMP), 
a secondary messenger that induces vasodilation by 
reducing intracellular calcium levels, thereby relaxing 
the smooth muscle cells. The relaxation of smooth 
muscle results in the widening of the blood vessels 
(vasodilation), which lowers vascular resistance and 
promotes blood flow. This process is vital for regulating 
blood pressure and ensuring that oxygen and nutrients 
are delivered efficiently to tissues throughout the body 
11-12. 

In addition to its vasodilatory effects, NO has several 
other important functions in endothelial homeostasis. It 
acts as an anti-inflammatory agent by inhibiting the 
adhesion of leukocytes to the endothelial cells, which 
helps prevent excessive inflammation and tissue 
damage. Furthermore, NO exerts anti-thrombotic effects 
by inhibiting platelet aggregation and promoting 
fibrinolysis. This prevents the formation of clots that 
could obstruct blood vessels and disrupt blood flow. NO 
also plays a role in regulating vascular permeability, 
ensuring that the endothelial barrier remains intact to 
prevent unwanted leakage of plasma proteins into 
tissues 13. However, the bioavailability of NO can be 

compromised in various pathological conditions, 
including sickle cell disease (SCD). In SCD, a 
combination of factors such as increased oxidative 
stress, chronic hemolysis, and the release of free 
hemoglobin leads to a significant reduction in NO levels. 
Free hemoglobin, released from lysed red blood cells, 
scavenges NO, reducing its availability and impairing its 
vasodilatory effects. This contributes to endothelial 
dysfunction, characterized by a shift toward 
vasoconstriction, increased leukocyte adhesion, and a 
pro-thrombotic state. These changes underlie many of 
the vascular complications seen in SCD, including vaso-
occlusive crises, pulmonary hypertension, and organ 
damage 14-15. In addition to hemolysis, other factors 
contribute to NO depletion in SCD. Arginase, an enzyme 
that metabolizes L-arginine, the precursor for NO 
synthesis, is upregulated in SCD. This results in a 
competition for L-arginine between arginase and eNOS, 
further limiting the substrate available for NO 
production. As a result, endothelial cells in SCD patients 
are less capable of producing NO, exacerbating 
endothelial dysfunction and contributing to the vascular 
complications associated with the disease 16. 

Mechanisms of Nitric Oxide Depletion in Sickle 
Cell Disease (SCD) 

In sickle cell disease (SCD), the bioavailability of nitric 
oxide (NO) is significantly reduced, contributing to 
vascular dysfunction, inflammation, and other severe 
complications. Several interrelated mechanisms are 
responsible for the depletion of NO in SCD, including 
chronic hemolysis, oxidative stress, upregulation of 
arginase, and endothelial dysfunction. These 
mechanisms work synergistically, creating a vicious 
cycle that exacerbates the clinical manifestations of the 
disease. 

1. Free Hemoglobin Scavenging of NO 

One of the primary mechanisms of NO depletion in SCD 
is the release of free hemoglobin into the bloodstream 
due to the chronic hemolysis of sickled red blood cells. 
When red blood cells become deformed and brittle, they 
rupture prematurely, releasing hemoglobin into the 
plasma. This free hemoglobin binds directly to NO, 
forming a nitrosylated product, which effectively 
inactivates NO and reduces its bioavailability. The 
scavenging of NO by free hemoglobin is particularly 
problematic because it prevents NO from performing its 
normal vasodilatory function, leading to 
vasoconstriction, increased blood pressure, and reduced 
tissue oxygenation. This process is thought to contribute 
significantly to the vascular complications observed in 
SCD, such as pulmonary hypertension and stroke 17. 

2. Oxidative Stress and Impaired Endothelial Nitric 
Oxide Synthase (eNOS) Activity 

Oxidative stress plays a crucial role in the depletion of 
NO in SCD. The chronic hemolysis of sickled cells leads 
to the release of heme, which induces the generation of 
reactive oxygen species (ROS) and reactive nitrogen 
species (RNS). These highly reactive molecules not only 
damage endothelial cells but also impair the function of 
endothelial nitric oxide synthase (eNOS), the enzyme 



Emmanuel Ifeanyi Obeagu                                                                                                        Asian Journal of Dental and Health Sciences. 2025; 5(3):6-12 

[8]                                                                                                                                                                                                                                              AJDHS.COM 

responsible for the production of NO. ROS can induce 
the uncoupling of eNOS, which converts it from a NO-
producing enzyme to a superoxide-generating enzyme. 
The production of superoxide (O2−) further exacerbates 
oxidative stress and competes with NO, reducing its 
availability. This impairment in eNOS function is a 
critical contributor to endothelial dysfunction and the 
inability of blood vessels to dilate properly in response 
to NO 18. 

3. Upregulation of Arginase and Substrate 
Competition 

Another key mechanism of NO depletion in SCD is the 
increased activity of arginase, an enzyme that 
metabolizes L-arginine, the substrate required for NO 
synthesis by eNOS. In SCD, arginase levels are elevated 
due to the stress and inflammation caused by hemolysis. 
Arginase hydrolyzes L-arginine into ornithine and urea, 
thereby reducing the amount of L-arginine available for 
eNOS to produce NO. This competition for L-arginine 
between eNOS and arginase is a critical factor in the 
depletion of NO. As arginase activity increases, the 
substrate for NO production becomes limited, 
exacerbating the deficit of NO in the circulation and 
contributing to the persistence of vascular dysfunction 
in SCD 19. 

4. Hemolysis-Induced Inflammation and Immune 
Activation 

The ongoing hemolysis in SCD also triggers a cascade of 
inflammatory responses that further contribute to NO 
depletion. The release of cell-free hemoglobin and other 
hemolytic products activates the innate immune system, 
leading to the production of pro-inflammatory cytokines 
and the recruitment of leukocytes to the site of injury. 
Inflammation increases the production of ROS and RNS, 
which not only damage endothelial cells but also reduce 
the bioavailability of NO. Additionally, pro-inflammatory 
cytokines such as tumor necrosis factor-alpha (TNF-α) 
and interleukin-6 (IL-6) can downregulate eNOS 
expression, further impairing NO synthesis and 
exacerbating endothelial dysfunction 20. 

5. Impaired Nitric Oxide Synthase Coupling and eNOS 
Dysfunction 

The activity of eNOS in SCD is further compromised by 
factors such as oxidative stress and altered redox status. 
Under normal conditions, eNOS functions as a dimer, 
efficiently converting L-arginine into NO. However, in 
the presence of excessive ROS and oxidative stress, 
eNOS can become uncoupled, meaning that instead of 
producing NO, it generates superoxide radicals. This 
uncoupling of eNOS not only contributes to a decrease 
in NO bioavailability but also increases the burden of 
oxidative stress, further damaging endothelial cells and 
exacerbating vascular dysfunction. This dysfunctional 
form of eNOS accelerates the pathological cycle of 
vascular injury in SCD 21. 

6. Implications for Vascular Dysfunction and Clinical 
Outcomes 

The depletion of NO in SCD has significant implications 
for vascular function and the progression of disease 

complications. The reduced NO bioavailability leads to 
endothelial dysfunction, characterized by impaired 
vasodilation, increased platelet aggregation, and 
enhanced leukocyte adhesion to the endothelium. These 
changes contribute to the formation of microvascular 
occlusions and increase the risk of thromboembolic 
events, which are common in SCD. Furthermore, 
impaired NO signaling is associated with the 
development of pulmonary hypertension, a leading 
cause of morbidity and mortality in SCD patients. By 
promoting vasoconstriction, oxidative stress, and 
thrombotic events, NO depletion exacerbates the 
severity of acute vaso-occlusive crises and contributes 
to long-term vascular complications, such as stroke, 
organ damage, and chronic kidney disease 22. 

Vascular Consequences of Nitric Oxide 
Deficiency in Sickle Cell Disease (SCD) 

Nitric oxide (NO) plays an essential role in maintaining 
vascular health by regulating blood vessel tone, 
inhibiting platelet aggregation, reducing inflammation, 
and preventing vascular smooth muscle cell 
proliferation. In sickle cell disease (SCD), a deficiency in 
NO bioavailability has profound consequences for 
vascular function, leading to a variety of complications 
that significantly impact patient outcomes. These 
vascular consequences are primarily driven by the loss 
of NO's vasodilatory effects, the promotion of 
vasoconstriction, and the dysregulation of endothelial 
function, which together contribute to the 
pathophysiology of SCD. 

1. Endothelial Dysfunction 

Endothelial cells are critical in regulating vascular tone 
and maintaining the integrity of the vascular wall. In 
SCD, the reduced bioavailability of NO leads to 
endothelial dysfunction, a state where the endothelium 
loses its ability to respond to stimuli that would 
normally induce vasodilation. The endothelial 
dysfunction in SCD is primarily a consequence of 
impaired NO signaling due to free hemoglobin 
scavenging NO, oxidative stress, and reduced eNOS 
activity. As a result, the endothelial cells become less 
capable of modulating blood vessel constriction and 
dilation, leading to a persistent state of vasoconstriction, 
which impairs blood flow. This diminished capacity to 
regulate vascular tone can result in various clinical 
manifestations, including chronic pain and ischemia 23. 

2. Increased Vascular Tone and Vasoconstriction 

In a healthy vasculature, NO promotes vasodilation by 
activating soluble guanylate cyclase in smooth muscle 
cells, leading to the relaxation of vascular smooth 
muscle and subsequent vessel widening. In SCD, 
however, the depletion of NO causes a shift toward 
vasoconstriction, as the smooth muscle cells no longer 
receive the signal to relax. This increase in vascular tone 
can lead to increased blood pressure and reduced 
perfusion of tissues and organs. The reduced 
vasodilation also contributes to the pathogenesis of 
vaso-occlusive crises, which are a hallmark of SCD. 
During a vaso-occlusive crisis, blood vessels become 
obstructed due to the combination of increased 



Emmanuel Ifeanyi Obeagu                                                                                                        Asian Journal of Dental and Health Sciences. 2025; 5(3):6-12 

[9]                                                                                                                                                                                                                                              AJDHS.COM 

viscosity, decreased nitric oxide levels, and abnormal 
red blood cell shapes, leading to ischemia and pain 25. 

3. Promotion of Thrombosis and Coagulation 

NO has anti-thrombotic properties, as it inhibits platelet 
aggregation and prevents the formation of blood clots. 
In the absence of sufficient NO, there is a heightened 
risk of thrombosis in SCD patients. The reduced 
bioavailability of NO in SCD promotes platelet 
activation, increases endothelial cell adhesion 
molecules, and enhances the recruitment of leukocytes 
and platelets to the site of injury. These processes 
contribute to the formation of microthrombi within the 
blood vessels, which can exacerbate vaso-occlusion and 
lead to further ischemia. Additionally, the 
prothrombotic state increases the risk of stroke, 
myocardial infarction, and other thromboembolic 
events in individuals with SCD 26. 

4. Increased Leukocyte Adhesion and Inflammation 

NO plays a critical role in modulating the inflammatory 
response within the vasculature by inhibiting the 
adhesion of leukocytes to the endothelial cells. In the 
absence of adequate NO levels, the inflammatory 
response is dysregulated, and there is increased 
adhesion of leukocytes to the endothelium. This 
exacerbates the inflammatory processes in SCD, 
promoting further endothelial injury and contributing 
to the development of chronic inflammation. The 
enhanced leukocyte adhesion also facilitates the 
progression of tissue damage and vascular occlusion, 
which underlie many of the acute and chronic 
complications seen in SCD patients, such as organ 
damage, stroke, and pulmonary hypertension 27. 

5. Pulmonary Hypertension 

Pulmonary hypertension (PH) is a common and severe 
complication in SCD, characterized by elevated pressure 
in the pulmonary arteries. NO deficiency plays a central 
role in the pathogenesis of PH in SCD. In the pulmonary 
circulation, NO normally helps regulate vascular tone 
and maintain a low-pressure environment. However, in 
the setting of NO depletion, there is increased 
pulmonary vascular resistance, which leads to right 
heart strain and eventually right heart failure. The 
combination of chronic hemolysis, oxidative stress, and 
impaired eNOS function in SCD promotes 
vasoconstriction in the pulmonary vasculature, 
worsening pulmonary hypertension. PH is a significant 
contributor to morbidity and mortality in SCD patients, 
with a poor prognosis if left untreated 28. 

6. End-organ Damage 

The vascular consequences of NO deficiency extend to 
various organs, where the impaired blood flow and 
increased vascular tone contribute to end-organ 
damage. Chronic kidney disease, stroke, and liver 
dysfunction are common complications in individuals 
with SCD, and the reduced NO bioavailability 
exacerbates these conditions. In the kidneys, the 
increased vascular tone and reduced perfusion can lead 
to glomerular injury and tubulointerstitial fibrosis, 
ultimately resulting in chronic kidney disease. Similarly, 

the combination of vaso-occlusion and endothelial 
dysfunction in the brain increases the risk of ischemic 
stroke in SCD patients. Organ damage in SCD is 
multifactorial but is aggravated by the diminished 
capacity of NO to protect against vascular injury and 
maintain normal blood flow 29. 

Therapeutic Strategies to Restore Nitric Oxide 
Bioavailability in Sickle Cell Disease (SCD) 

Restoring nitric oxide (NO) bioavailability is an 
important therapeutic target in sickle cell disease (SCD), 
as the deficiency of NO contributes significantly to the 
vascular dysfunction, inflammation, and thrombotic 
complications characteristic of the disease. Various 
therapeutic strategies have been explored to enhance 
NO production, minimize its scavenging, and improve 
endothelial function in individuals with SCD. These 
strategies involve both pharmacological interventions 
and lifestyle modifications aimed at restoring 
endothelial homeostasis, reducing oxidative stress, and 
improving vascular function. 

1. L-Arginine Supplementation 

L-arginine is the amino acid substrate required for the 
production of NO by endothelial nitric oxide synthase 
(eNOS). In SCD, the bioavailability of L-arginine is often 
reduced due to the increased activity of arginase, which 
hydrolyzes L-arginine into ornithine. Supplementing 
with L-arginine has been investigated as a strategy to 
restore NO production by providing an additional 
substrate for eNOS. Clinical studies have shown that L-
arginine supplementation can improve endothelial 
function, reduce pulmonary artery pressure, and 
enhance vasodilation in SCD patients. While the results 
are promising, the effect of L-arginine supplementation 
may be variable, and its use should be considered 
alongside other therapies aimed at reducing oxidative 
stress and inflammation 30. 

2. Nitrate Therapy 

Nitrate therapy is another strategy to restore NO 
bioavailability in SCD. Nitrates are metabolized to 
release NO or NO-like species, which can help restore 
vasodilation and reduce vascular tone. Organic nitrates, 
such as nitroglycerin, and inorganic nitrates, such as 
sodium nitrite, have been explored in preclinical and 
clinical studies for their ability to increase NO levels in 
the circulation. In SCD, nitrate therapy may improve 
endothelial function, reduce pulmonary hypertension, 
and alleviate symptoms of vaso-occlusive crises by 
enhancing blood flow and reducing ischemia. However, 
the long-term use of nitrates in SCD requires caution 
due to the potential for tolerance development and 
adverse effects on blood pressure regulation 31. 

3. Antioxidant Therapies 

Since oxidative stress is a key contributor to NO 
depletion in SCD, antioxidants that neutralize reactive 
oxygen species (ROS) and prevent endothelial cell 
damage have been investigated as therapeutic options. 
Vitamin E, a potent antioxidant, has been shown to 
reduce oxidative stress in SCD and may help improve 
NO bioavailability. Other antioxidant compounds, such 



Emmanuel Ifeanyi Obeagu                                                                                                        Asian Journal of Dental and Health Sciences. 2025; 5(3):6-12 

[10]                                                                                                                                                                                                                                              AJDHS.COM 

as N-acetylcysteine (NAC) and polyphenols (found in 
fruits, vegetables, and tea), have demonstrated potential 
in reducing ROS and improving endothelial function. 
These antioxidants may indirectly enhance NO signaling 
by decreasing the oxidative damage to eNOS and other 
endothelial cell components. The use of antioxidants as 
adjunctive therapies may be effective in managing 
vascular dysfunction and improving overall patient 
health in SCD 32. 

4. Hydroxyurea Therapy 

Hydroxyurea, a standard therapeutic agent in SCD, has 
demonstrated multiple benefits beyond its effects on 
hemoglobin F (HbF) induction. One of its potential 
benefits is its ability to increase NO production. 
Hydroxyurea has been shown to stimulate eNOS activity 
and enhance NO bioavailability in patients with SCD. 
This effect is thought to be mediated by the reduction of 
hemolysis and the associated release of free 
hemoglobin, which scavenges NO. Additionally, 
hydroxyurea can decrease oxidative stress, thereby 
protecting endothelial cells and promoting vascular 
health. The combination of these effects may help 
mitigate the vascular complications of SCD, including 
pulmonary hypertension and stroke. Hydroxyurea 
remains one of the cornerstones of SCD treatment due 
to its ability to reduce the frequency of vaso-occlusive 
crises and improve overall patient outcomes 33. 

5. Gene Therapy and Cellular Approaches 

Emerging gene therapy and cellular approaches offer 
promising potential for restoring NO bioavailability in 
SCD. Recent advances in gene editing technologies, such 
as CRISPR-Cas9, have made it possible to correct the 
underlying genetic mutation in hemoglobin (HbS) or to 
induce the expression of fetal hemoglobin (HbF), which 
reduces the sickling of red blood cells and alleviates 
hemolysis. By reducing hemolysis and increasing HbF 
levels, gene therapy may reduce the amount of free 
hemoglobin available to scavenge NO. Additionally, stem 
cell-based therapies, including the use of autologous 
stem cells genetically modified to express HbF, may 
improve blood flow and endothelial function by 
reducing hemolysis and inflammation. While these 
approaches are still in experimental stages, they hold 
great promise for long-term management of SCD and its 
associated vascular complications 34. 

6. Phosphodiesterase Type 5 (PDE5) Inhibitors 

PDE5 inhibitors, such as sildenafil, are known to 
enhance NO signaling by inhibiting the breakdown of 
cyclic guanosine monophosphate (cGMP), which is 
produced in response to NO activation of guanylate 
cyclase. By preserving cGMP levels, PDE5 inhibitors can 
enhance the vasodilatory effects of NO and improve 
endothelial function. In SCD, PDE5 inhibitors have been 
explored as potential therapies for pulmonary 
hypertension and other forms of vascular dysfunction. 
Clinical studies have shown that sildenafil and other 
PDE5 inhibitors can improve exercise capacity, reduce 
pulmonary artery pressure, and alleviate symptoms of 
pulmonary hypertension in SCD patients. While these 
drugs are generally well tolerated, careful monitoring is 

necessary due to potential side effects and interactions 
with other medications used in SCD management 35-36. 

7. Lifestyle Modifications 

In addition to pharmacological interventions, lifestyle 
modifications can play a key role in restoring NO 
bioavailability in SCD. Regular physical activity has been 
shown to increase endothelial NO production and 
improves vascular health. Exercise stimulates eNOS 
activity, increases blood flow, and helps maintain 
optimal vascular tone. Moreover, maintaining a healthy 
diet rich in antioxidants (such as fruits, vegetables, and 
whole grains) and omega-3 fatty acids can help reduce 
oxidative stress and promote NO production. Avoiding 
smoking and managing other cardiovascular risk 
factors, such as hypertension, can also improve NO 
bioavailability and reduce the risk of vascular 
complications in SCD 37. 

Conclusion 

Restoring nitric oxide (NO) bioavailability in sickle cell 
disease (SCD) represents a critical therapeutic strategy 
to address the vascular dysfunction and associated 
complications that significantly impact patient quality of 
life and longevity. The depletion of NO in SCD is a 
central mechanism underlying endothelial dysfunction, 
increased vascular tone, thrombosis, and inflammation. 
These pathophysiological processes contribute to many 
of the hallmark complications of the disease, including 
vaso-occlusive crises, pulmonary hypertension, stroke, 
and organ damage. Therapeutic interventions aimed at 
enhancing NO bioavailability, such as L-arginine 
supplementation, nitrate therapy, antioxidant 
treatment, hydroxyurea, and PDE5 inhibitors, show 
promise in improving vascular health in SCD patients. 
Additionally, emerging gene therapies and stem cell-
based approaches offer the potential for long-term 
improvements by targeting the root causes of NO 
depletion, such as hemolysis and oxidative stress. While 
these therapies are promising, they require careful 
clinical evaluation to ensure efficacy and safety in 
diverse patient populations. 

Conflict of Interest: Author declares no potential 

conflict of interest with respect to the contents, 

authorship, and/or publication of this article. 

Source of Support: Nil 

Funding: The authors declared that this study has 

received no financial support. 

Informed Consent Statement: Not applicable.  

Data Availability Statement: The data supporting in 

this paper are available in the cited references.  

Ethics approval: Not applicable. 

References 

1. Gupta A. Sickle Cell Anemia and Related Hemoglobinopathies. 
InDecision Making Through Problem Based Learning in 
Hematology: A Step-by-Step Approach in patients with Anemia 
2024: 269-289. Singapore: Springer Nature Singapore. 
https://doi.org/10.1007/978-981-99-8933-1_21 

https://doi.org/10.1007/978-981-99-8933-1_21


Emmanuel Ifeanyi Obeagu                                                                                                        Asian Journal of Dental and Health Sciences. 2025; 5(3):6-12 

[11]                                                                                                                                                                                                                                              AJDHS.COM 

2. Hassan MS, Nasrin T, Mahalka A, Hoque M, Ali S. A perspective on 
the genesis, diagnostics, and management of sickle cell disease. 
Egyptian Journal of Medical Human Genetics. 2024; 25(1):150. 
https://doi.org/10.1186/s43042-024-00623-1 

3. Rajput HS, Kumari M, Talele C, Sajan C, Saggu V, Hadia R. 
Comprehensive Overview Of Sickle Cell Disease: Global Impact, 
Management Strategies, And Future Directions. Journal of 
Advanced Zoology. 2024; 45(1). 
https://doi.org/10.53555/jaz.v45i1.3390 

4. Obeagu EI. Role of Autophagy in Modulating Oxidative Stress in 
Sickle Cell Disease: A Narrative Review. Int. J. Curr. Res. Chem. 
Pharm. Sci. 2024;11(8):38-46. https://doi.org/10.23880/hij-
16000247 

5. Obeagu EI. Redox Regulation of Hemoglobin in Sickle Cell Disease: A 
Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(8):13-9. 

6. Obeagu EI, Bunu UO, Obeagu GU, Habimana JB. Antioxidants in the 
management of sickle cell anaemia: an area to be exploited for the 
wellbeing of the patients. Int Res Med Health Sci. 2023 Sep 
11;6:12-7. 

7. Xiao R, Li L, Zhang Y, Fang L, Li R, Song D, Liang T, Su X. Reducing 
carbon and nitrogen loss by shortening the composting duration 
based on seed germination index (SCD@ GI): feasibilities and 
challenges. Science of The Total Environment. 2024:172883. 
https://doi.org/10.1016/j.scitotenv.2024.172883 
PMid:38697528 

8. Lin W, Lv X, Wang Q, Li L, Zou G. Nitrogen concentration dependent 
optical defects transition in single crystal diamond through low 
pressure high temperature annealing. Vacuum. 2025:114329. 
https://doi.org/10.1016/j.vacuum.2025.114329 

9. Wood KC, Granger DN. Sickle cell disease: role of reactive oxygen 
and nitrogen metabolites. Clinical & Experimental Pharmacology 
& Physiology. 2007 Sep 1;34(9). https://doi.org/10.1111/j.1440-
1681.2007.04639.x PMid:17645642 

10. Dijkmans T, Djokic MR, Van Geem KM, Marin GB. Comprehensive 
compositional analysis of sulfur and nitrogen containing 
compounds in shale oil using GC× GC-FID/SCD/NCD/TOF-MS. 
Fuel. 2015; 140:398-406. 
https://doi.org/10.1016/j.fuel.2014.09.055 

11. Muehle M, Asmussen J, Becker MF, Schuelke T. Extending 
microwave plasma assisted CVD SCD growth to pressures of 400 
Torr. Diamond and Related Materials. 2017; 79:150-163. 
https://doi.org/10.1016/j.diamond.2017.09.013 

12. Obeagu EI, Obeagu GU. Immunization strategies for individuals 
with sickle cell anemia: A narrative review. Medicine. 2024; 
103(38):e39756. 
https://doi.org/10.1097/MD.0000000000039756 
PMid:39312357 PMCid:PMC11419550 

13. Obeagu EI. Strategies for reducing child mortality due to sickle cell 
disease in Uganda: a narrative review. Annals of Medicine and 
Surgery.:10-97. 

14. Obeagu EI. Erythropoeitin in sickle cell anaemia: a review. 
International Journal of Research Studies in Medical and Health 
Sciences. 2020;5(2):22-8. 
https://doi.org/10.22259/ijrsmhs.0502004 

15. Obeagu EI, Obeagu GU. Malnutrition in sickle cell anemia: 
prevalence, impact, and interventions: a review. Medicine. 2024 
May 17;103(20):e38164. 
https://doi.org/10.1097/MD.0000000000038164 
PMid:38758879 PMCid:PMC11098235 

16. Quemada M, Delgado A, Mateos L, Villalobos FJ. Nitrogen 
fertilization I: The nitrogen balance. InPrinciples of agronomy for 
sustainable agriculture 2024: 377-401. Cham: Springer 
International Publishing. https://doi.org/10.1007/978-3-031-
69150-8_26 

17. Krug EC, Winstanley D. The need for comprehensive and 
consistent treatment of the nitrogen cycle in nitrogen cycling and 
mass balance studies: I. Terrestrial nitrogen cycle. Science of the 
total environment. 2002; 293(1-3):1-29. 

https://doi.org/10.1016/S0048-9697(01)01133-0 
PMid:12109464 

18. Zhang CC, Zhou CZ, Burnap RL, Peng L. Carbon/nitrogen metabolic 
balance: lessons from cyanobacteria. Trends in plant science. 
2018; 23(12):1116-1130. 
https://doi.org/10.1016/j.tplants.2018.09.008 PMid:30292707 

19. Enwonwu CO, Xu XX, Turner E. Nitrogen metabolism in sickle cell 
anemia: free amino acids in plasma and urine. The American 
journal of the medical sciences. 1990; 300(6):366-371. 
https://doi.org/10.1097/00000441-199012000-00005 
PMid:2264574 

20. Borel MJ, Buchowski MS, Turner EA, Peeler BB, Goldstein RE, 
Flakoll PJ. Alterations in basal nutrient metabolism increase 
resting energy expenditure in sickle cell disease. American Journal 
of Physiology-Endocrinology and Metabolism. 1998; 274(2):E357-
364. https://doi.org/10.1152/ajpendo.1998.274.2.E357 
PMid:9486169 

21. Jackson AA. The use of stable isotopes to study nitrogen 
metabolism in homozygous sickle cell disease. InGenetic factors in 
nutrition. 1984: 297-315. Academic Press, New York. 
https://doi.org/10.1016/B978-0-12-715950-8.50024-X 
PMCid:PMC7131065 

22. Schnog JJ, Jager EH, van der Dijs FP, Duits AJ, Moshage H, Muskiet 
FD, Muskiet FA. Evidence for a metabolic shift of arginine 
metabolism in sickle cell disease. Annals of Hematology. 2004; 
83:371-375. https://doi.org/10.1007/s00277-004-0856-9 
PMid:15054669 

23. Darghouth D, Koehl B, Madalinski G, Heilier JF, Bovee P, Xu Y, 
Olivier MF, Bartolucci P, Benkerrou M, Pissard S, Colin Y. 
Pathophysiology of sickle cell disease is mirrored by the red blood 
cell metabolome. Blood, The Journal of the American Society of 
Hematology. 2011; 117(6):e57-66. 
https://doi.org/10.1182/blood-2010-07-299636 PMid:21135259 

24. Morris CR, Kato GJ, Poljakovic M, Wang X, Blackwelder WC, 
Sachdev V, Hazen SL, Vichinsky EP, Morris SM, Gladwin MT. 
Dysregulated arginine metabolism, hemolysis-associated 
pulmonary hypertension, and mortality in sickle cell disease. 
Jama. 2005; 294(1):81-90. 
https://doi.org/10.1001/jama.294.1.81 PMid:15998894 
PMCid:PMC2065861 

25. Zhou Y, Yu X, Nicely A, Cunningham G, Challa C, McKinley K, Nickel 
R, Campbell A, Darbari D, Summar M, Majumdar S. Amino acid 
signature during sickle cell pain crisis shows significant 
alterations related to nitric oxide and energy metabolism. 
Molecular genetics and metabolism. 2022; 137(1-2):146-152. 
https://doi.org/10.1016/j.ymgme.2022.08.004 PMid:36030599 

26. D'Alessandro A, Nouraie SM, Zhang Y, Cendali F, Gamboni F, Reisz 
JA, Zhang X, Bartsch KW, Galbraith MD, Espinosa JM, Gordeuk VR. 
Metabolic signatures of cardiorenal dysfunction in plasma from 
sickle cell patients as a function of therapeutic transfusion and 
hydroxyurea treatment. Haematologica. 2023; 108(12):3418. 
https://doi.org/10.3324/haematol.2023.283288 PMid:37439373 
PMCid:PMC10690926 

27. Obeagu EI, Prajapati SK, Maurya SD, Maternal Anemia in the 
Context of Infectious Diseases during Pregnancy: A Review, 
International Journal of Medical Sciences and Pharma Research, 
2025;11(1):8-13 https://doi.org/10.22270/ijmspr.v11i1.134 

28. Obeagu EI, Chukwu PH. Inclusive Healthcare Approaches for HIV-
Positive Sickle Cell Disease Patients: A Review. Current Research 
in Biological Sciences. 2025;1(1):01-8. 

29. Obeagu EI, Obeagu GU. Managing gastrointestinal challenges: 
diarrhea in sickle cell anemia. Medicine. 2024; 103(18):e38075. 
https://doi.org/10.1097/MD.0000000000038075 
PMid:38701274 PMCid:PMC11062666 

30. Obeagu EI, Obeagu GU. Living with sickle cell in Uganda: A 
comprehensive perspective on challenges, coping strategies, and 
health interventions. Medicine. 2024 Dec 20;103(51):e41062. 
https://doi.org/10.1097/MD.0000000000041062 
PMid:39705436 PMCid:PMC11666137 

https://doi.org/10.1186/s43042-024-00623-1
https://doi.org/10.53555/jaz.v45i1.3390
https://doi.org/10.23880/hij-16000247
https://doi.org/10.23880/hij-16000247
https://doi.org/10.1016/j.scitotenv.2024.172883
https://doi.org/10.1016/j.vacuum.2025.114329
https://doi.org/10.1111/j.1440-1681.2007.04639.x
https://doi.org/10.1111/j.1440-1681.2007.04639.x
https://doi.org/10.1016/j.fuel.2014.09.055
https://doi.org/10.1016/j.diamond.2017.09.013
https://doi.org/10.1097/MD.0000000000039756
https://doi.org/10.22259/ijrsmhs.0502004
https://doi.org/10.1097/MD.0000000000038164
https://doi.org/10.1007/978-3-031-69150-8_26
https://doi.org/10.1007/978-3-031-69150-8_26
https://doi.org/10.1016/S0048-9697(01)01133-0
https://doi.org/10.1016/j.tplants.2018.09.008
https://doi.org/10.1097/00000441-199012000-00005
https://doi.org/10.1152/ajpendo.1998.274.2.E357
https://doi.org/10.1016/B978-0-12-715950-8.50024-X
https://doi.org/10.1007/s00277-004-0856-9
https://doi.org/10.1182/blood-2010-07-299636
https://doi.org/10.1001/jama.294.1.81
https://doi.org/10.1016/j.ymgme.2022.08.004
https://doi.org/10.3324/haematol.2023.283288
https://doi.org/10.22270/ijmspr.v11i1.134
https://doi.org/10.1097/MD.0000000000038075
https://doi.org/10.1097/MD.0000000000041062


Emmanuel Ifeanyi Obeagu                                                                                                        Asian Journal of Dental and Health Sciences. 2025; 5(3):6-12 

[12]                                                                                                                                                                                                                                              AJDHS.COM 

31. Obeagu EI, Adias TC, Obeagu GU. Advancing life: innovative 
approaches to enhance survival in sickle cell anemia patients. 
Annals of Medicine and Surgery. 2024; 86(10):6021-6036. 
https://doi.org/10.1097/MS9.0000000000002534 
PMid:39359845 PMCid:PMC11444627 

32. Bell V, Varzakas T, Psaltopoulou T, Fernandes T. Sickle cell disease 
update: new treatments and challenging nutritional interventions. 
Nutrients. 2024; 16(2):258. 
https://doi.org/10.3390/nu16020258 PMid:38257151 
PMCid:PMC10820494 

33. Khan SA, Damanhouri G, Ali A, Khan SA, Khan A, Bakillah A, Marouf 
S, Al Harbi G, Halawani SH, Makki A. Precipitating factors and 
targeted therapies in combating the perils of sickle cell disease---A 
special nutritional consideration. Nutrition & metabolism. 2016; 
13:1-2. https://doi.org/10.1186/s12986-016-0109-7 
PMid:27508000 PMCid:PMC4977632 

34. Patel S, Patel R, Mukkala SR, Akabari A. Emerging therapies and 
management approaches in sickle cell disease (SCD): A critical 
review. Journal of Phytonanotechnology and Pharmaceutical 
Sciences. 2023; 3(3):1-1. 
https://doi.org/10.54085/jpps.2023.3.3.3 

35. Obeagu EI, Prajapati SK, Maurya SD, Anemia in Pregnancy: 
Exploring Non-Iron Deficiency Causes, International Journal of 
Medical Sciences and Pharma Research, 2025;11(1):1-7 
https://doi.org/10.22270/ijmspr.v11i1.130 

36. Boma PM, Kaponda AA, Panda J, Bonnechère B. Enhancing the 
management of pediatric sickle cell disease by integrating 
functional evaluation to mitigate the burden of vaso-occlusive 
crises. Journal of Vascular Diseases. 2024; 3(1):77-87. 
https://doi.org/10.3390/jvd3010007 

37. Obeagu EI, Chukwu PH. Inclusive Healthcare Approaches for HIV-
Positive Sickle Cell Disease Patients: A Review. Current Research 
in Biological Sciences. 2025;1(1):01-8. 

 

 

https://doi.org/10.1097/MS9.0000000000002534
https://doi.org/10.3390/nu16020258
https://doi.org/10.1186/s12986-016-0109-7
https://doi.org/10.54085/jpps.2023.3.3.3
https://doi.org/10.22270/ijmspr.v11i1.130
https://doi.org/10.3390/jvd3010007

